A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

Summary

The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).

Timeline

Start

2021-09-06

Primary completion

2022-03-18

Completion

2022-03-18

Outcome

Outcome not reported

Stopped (Business): “Janssen made the strategic decision to discontinue the DAISY study. This decision is not based on any safety concerns.”

Drugs

Indications